TY - JOUR
T1 - Diagnoses of depression and anxiety versus current symptoms and quality of life in multiple sclerosis
AU - the CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS)
AU - Marrie, Ruth Ann
AU - Patten, Scott B.
AU - Berrigan, Lindsay I.
AU - Tremlett, Helen
AU - Wolfson, Christina
AU - Warren, Sharon
AU - Leung, Stella
AU - Fiest, Kirsten M.
AU - McKay, Kyla A.
AU - Fisk, John D.
AU - Blanchard, James
AU - Caetano, Patricia
AU - Elliott, Lawrence
AU - Yu, Bo Nancy
AU - Bhan, Virender
AU - Profetto-McGrath, Joanne
AU - Svenson, Larry
AU - Jette, Nathalie
AU - Zhu, Bin
AU - Wang, Yan
AU - Hall, Nicholas
AU - Zhu, Feng
AU - Kingwell, Elaine
AU - Stadnyk, Karen
N1 - Funding Information:
Canadian Institutes of Health Research (CIHR) Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis investigators (ECoMS; by site): University of Manitoba (James Blanchard, MD, PhD; Patricia Caetano, PhD; Lawrence Elliott, MD, MSc; Ruth Ann Marrie, MD, PhD; Bo Nancy Yu, MD, PhD); Dalhousie University (Virender Bhan, MBBS; John D. Fisk, PhD), University of Alberta (Joanne Profetto-McGrath, PhD; Sharon Warren, PhD; Larry Svenson, BSc); McGill University (Christina Wolfson, PhD); University of British Columbia (Helen Tremlett, PhD); and University of Calgary (Nathalie Jette, MD, MSc; Scott Patten, MD, PhD). Analysts (by site): University of Manitoba (Stella Leung); McGill University (Bin Zhu); and Dalhousie University (Yan Wang). Contributors (by site): Nicholas Hall, BSc (University of Manitoba, study coordinator); Feng Zhu, PhD (University of British Columbia, analytic support); Elaine Kingwell, PhD (University of British Columbia, study coordination support), and Karen Stadnyk, MSc (Dalhousie University, study coordinator).
Publisher Copyright:
© 2018 Consortium of Multiple Sclerosis Centers.
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Background: Studies assessing the prevalence of depression and anxiety in multiple sclerosis (MS) have used various ascertainment methods that capture different constructs. The relationships between these methods are incompletely understood. Psychiatric comorbidity is associated with lower health-related quality of life (HRQOL) in MS, but the effects of past diagnoses of depression and anxiety on HRQOL are largely unknown. We compared the prevalence of depression and anxiety in persons with MS using administrative data, self-reported physician diagnoses, and symptom-based measures and compared characteristics of persons classified as depressed or anxious by each method. We evaluated whether HRQOL was most affected by previous diagnoses of depression or anxiety or by current symptoms. Methods: We linked clinical and administrative data for 859 participants with MS. HRQOL was measured by the Health Utilities Index Mark 3. We classified participants as depressed or anxious using administrative data, self-reported physician diagnoses, and the Hospital Anxiety and Depression Scale. Multivariable linear regression examined whether diagnosed depression or anxiety affected HRQOL after accounting for current symptoms. Results: Lifetime prevalence estimates for depression were approximately 30% regardless of methods used, but 35.8% with current depressive symptoms were not captured by either administrative data or selfreported diagnoses. Prevalence estimates of anxiety ranged from 11% to 19%, but 65.6% with current anxiety were not captured by either administrative data or self-reported diagnoses. Previous diagnoses did not decrease HRQOL after accounting for current symptoms. Conclusions: Depression and, to a greater extent, anxiety remain underdiagnosed and undertreated in MS; both substantially contribute to reduced HRQOL in MS.
AB - Background: Studies assessing the prevalence of depression and anxiety in multiple sclerosis (MS) have used various ascertainment methods that capture different constructs. The relationships between these methods are incompletely understood. Psychiatric comorbidity is associated with lower health-related quality of life (HRQOL) in MS, but the effects of past diagnoses of depression and anxiety on HRQOL are largely unknown. We compared the prevalence of depression and anxiety in persons with MS using administrative data, self-reported physician diagnoses, and symptom-based measures and compared characteristics of persons classified as depressed or anxious by each method. We evaluated whether HRQOL was most affected by previous diagnoses of depression or anxiety or by current symptoms. Methods: We linked clinical and administrative data for 859 participants with MS. HRQOL was measured by the Health Utilities Index Mark 3. We classified participants as depressed or anxious using administrative data, self-reported physician diagnoses, and the Hospital Anxiety and Depression Scale. Multivariable linear regression examined whether diagnosed depression or anxiety affected HRQOL after accounting for current symptoms. Results: Lifetime prevalence estimates for depression were approximately 30% regardless of methods used, but 35.8% with current depressive symptoms were not captured by either administrative data or selfreported diagnoses. Prevalence estimates of anxiety ranged from 11% to 19%, but 65.6% with current anxiety were not captured by either administrative data or self-reported diagnoses. Previous diagnoses did not decrease HRQOL after accounting for current symptoms. Conclusions: Depression and, to a greater extent, anxiety remain underdiagnosed and undertreated in MS; both substantially contribute to reduced HRQOL in MS.
UR - http://www.scopus.com/inward/record.url?scp=85045086313&partnerID=8YFLogxK
U2 - 10.7224/1537-2073.2016-110
DO - 10.7224/1537-2073.2016-110
M3 - Article
AN - SCOPUS:85045086313
SN - 1537-2073
VL - 20
SP - 76
EP - 84
JO - International Journal of MS Care
JF - International Journal of MS Care
IS - 2
ER -